Author

D. S. Neuberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. A. Lane· 1 shared C. A. G. Booth· 1 shared C. J. Wu· 1 shared C. Mangum· 1 shared C. Park· 1 shared C. Shin· 1 shared D. Abbondanza· 1 shared E. Azizi· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Lane

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy

K. Maurer, C. Park, S. Mani, M. Borji, L. Penter, Y. Jin, J. Y. Zhang, C. Shin, J. R. Brenner, J. Southard, S. Krishna, W. Lu, H. Lyu, D. Abbondanza, C. Mangum, , E. Azizi

The paper analyzes single-cell data from bone marrow samples to identify immune cell interactions that predict response to adoptive cellular therapy in myeloid leukemia.

bioRxiv · Feb 9, 2024 · PreprintCancer Biology

Targetable leukemia dependency on noncanonical PI3Kγ signaling

Q. Luo, E. G. Raulston, M. A. Prado, X. Wu, K. Gritsman, C. A. G. Booth, R. Xu, P. van Galen, J. G. Doench, S. Shimony, H. W. Long, D. S. Neuberg, J. A. Paulo, A. A. Lane

This study identifies a targetable dependency on noncanonical PI3Kγ signaling in acute leukemias, showing that PI3Kγ inhibition with eganelisib improves survival when combined with cytarabine.

bioRxiv · Dec 15, 2023 · PreprintCancer Biology